Business Context and Reporting Period
This Form 8-K Current Report was filed by The Ensign Group, Inc. on November 28, 2018. The filing addresses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of a new director to the Board of Directors. Effective November 28, 2018, Dr. Ann Scott Blouin was appointed to fill the vacancy created by the resignation of Malene Davis on August 4, 2018.
Management Commentary and Governance
- New Director Profile: Dr. Blouin brings over 30 years of experience in health care administration, consulting, and clinical nursing. She recently retired as Executive Vice President of Customer Relations at The Joint Commission.
- Professional Background: She has held senior leadership roles at community teaching hospitals and academic medical centers. Her consulting experience includes work with Deloitte, Ernst & Young, Cap Gemini, and Huron Consulting Group.
- Current Roles: Dr. Blouin serves as President of PSQ Advisory and sits on the Institute for Healthcare Improvement Board of Directors.
- Compensation: Her compensation will be consistent with that of other non-employee directors as described in the 2018 proxy statement.
- Committee Assignments: The Nomination and Corporate Governance Committee anticipates appointing Dr. Blouin to specific board committees at their next scheduled meeting.
Investor Verification Checklist
- Verify the effective date of Dr. Blouin's appointment (November 28, 2018).
- Confirm the specific board committees to which Dr. Blouin is assigned once the Nomination and Corporate Governance Committee meets.
- Review the 2018 proxy statement filed on April 12, 2018, for details on non-employee director compensation.
- Check for any subsequent filings regarding the resignation of Malene Davis to ensure no undisclosed related party transactions exist.